Insights

Is the CSL (ASX:CSL) share price too cheap to ignore?

The CSL Limited (ASX:CSL) share price is down 21% from its 52-week high. Is this a buying opportunity for investors next week?
The post Is the CSL (ASX:CSL) share price too cheap to ignore? appeared first on The Motley Fool Australia. –

healthcare asx share price flat represented by doctor shrugging

It has been an unusually disappointing year for the CSL Limited (ASX: CSL) share price.

The biotechnology giant’s shares have thoroughly underperformed the market during this time and are trading significantly lower than their 52-week high.

In fact, with the CSL share price currently fetching $263.40, it is down 21% from its high of $332.68.

Why is the CSL share price under pressure?

The weakness in the CSL share price has been driven largely by concerns over plasma collection headwinds.

As well as being impacted by social distancing initiatives, COVID stimulus payments have prevented some traditional donors from donating. This has led to a reduction in supply and an increase in costs.

Given how plasma is a vital component in many of CSL’s most lucrative therapies, this has the potential to weigh on margins in the short term.

However, it is important to understand that this is a temporary headwind and not structural. In light of this, once the pandemic passes, plasma collections should become far easier and costs should inevitably reduce.

In the meantime, increased demand for influenza vaccines looks set to offset some of this headwind.

Another concern that appears to be weighing on investor sentiment is Argenx’s FcRn CIDP therapy, which is under development. This has the potential to be a bit of a game changer in the industry and could steal away some immunoglobulin sales in the future.

Is this a buying opportunity?

A number of brokers believe that the CSL share price is trading at a very attractive level.

For example, UBS currently has a buy rating and $330.00 price target and Credit Suisse has an outperform rating and $315.00 price target.

UBS’ price target implies potential upside of 25% over the next 12 months. Whereas Credit Suisse’s price target represents upside of just under 20%.

It is also worth noting that the latter broker isn’t worried about Argenx’s FcRn CIDP therapy. Even if it were a success, the broker believes demand is growing strong enough to accommodate both therapies.

All in all, these brokers appear to believe that now would be an opportune time to buy CSL shares.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Is the CSL (ASX:CSL) share price too cheap to ignore? appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!